Entropy Neurodynamics

Entropy Neurodynamics Rule of 40

The Rule of 40 of Entropy Neurodynamics (ENP.AX) as of Nov 5, 2026 is -393.62 %. In the previous year, Rule of 40 was -362.69 % — a change of 8.53% (lower).

Rule of 40

-393.62 %

YoY

8.53%

Last updated:

Rule of 40 of Entropy Neurodynamics is 2025 -393.62 % . Rule of 40 of Entropy Neurodynamics was 2024 -362.69 % . It decreases by 8.53% lower compared to the previous year.

The Entropy Neurodynamics Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2023
-1,030.36 AUD
Jan 1, 2024
-362.69 AUD
Jan 1, 2025
-393.62 AUD
The Entropy Neurodynamics Rule of 40 history
YEARRule of 40YoY
-393.62 %+8.53%
-362.69 %-64.80%
-1,030.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Rule of 40 of Entropy Neurodynamics is -393.62 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Quality — Entropy Neurodynamics

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — Entropy Neurodynamics